Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Adam Laznicka, Nikola Curik, Jitka Krizkova, Katerina Rajnisova, Pavla Suchankova, Barbora Stefikova, Karyna Zhuk, Vaclava Polivkova, Eva Pokorna, Pavel Klener, Cyril Salek, Hana Klamova, Sarka Ransdorfova, Andreas Hochhaus, Katerina Machova Polakova

Blood (2025) 146 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2025-3284

Published: 2025

Journal Articles

Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)

Zuzana Vrzalova, Vaclava Polivkova, Jitka Krizkova, Stepan Hrabovsky, Zdenek Koristek, Jan Horacek, Pavla Suchankova, Hana Halamova, Barbara Dvorackova, Eva Froňková, Frantisek Folber, Michael Doubek, Katerina Machova Polakova, Cyril Salek

Blood (2025) 146 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2025-1587

Published: 2025

Journal Articles

BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months

Nicholas Cross, Thomas Ernst, Jenny Rinke, Hana Žižková, Alfred Cross, Katerina Machova Polakova, Birgit Spiess, William Tapper, Helen White, Andreas Hochhaus

Blood (2025) 146 (Supplement 1): 5553.

https://doi.org/10.1182/blood-2025-5553

Published: 2025

Journal Articles

Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions

Katerina Machova Polakova, Hana Žižková, Pavla Suchankova, Katerina Rajnisova, Katerina Blagoevova, Romana Vajnerova, Helen White, Andreas Hochhaus, Nicholas Cross

Blood (2025) 146 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2025-3762

Published: 2025

Journal Articles

Allele-dependent activity of promoters of genes SLC22A4 and SLC22A5 encoding imatinib transporters in chronic myeloid leukemia

Pavel Burda, Nikola Curik, Alzbeta Hlavackova, Vaclava Polivkova, Jitka Krizkova, Pavla Suchankova, Katerina Rajnisova, Jiri Suttnar, Cyril Salek, Katerina Machova Polakova

Blood (2025) 146 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2025-3756

Published: 2025

Journal Articles

DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from the clinical trial

Blood (2025) 146 (Supplement 1): 78.

https://doi.org/10.1182/blood-2025-78

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment

Jitka Krizkova, Vaclava Polivkova, Nikola Curik, Adam Laznicka, Adela Benesova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Jan Zuna, Marketa Zaliova, Jan Trka, Pavel Semerak, Tomas Kalina, Cyril Salek, Katerina Machova Polakova

Blood (2023) 142 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2023-189017

Published: 2023

Journal Articles

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Blood (2023) 142 (Supplement 1): 3166.

https://doi.org/10.1182/blood-2023-174455

Published: 2023

Journal Articles

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Blood (2023) 142 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2023-180355

Published: 2023

Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Blood (2021) 138 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2021-146221

Published: 2021

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorkova, Marketa Zaliova, Nicola C. Venn, Kirsten Bleckmann, Marie Trkova, Eliska Potuckova, Martina Vaskova, Jana Linhartova, Katerina Machova Polakova, Eva Fronkova, Walter Muskovic, Jodie E. Giles, Peter J. Shaw, Gunnar Cario, Rosemary Sutton, Jan Stary, Jan Trka, Jan Zuna

Blood (2017) 129 (20): 2771–2781.

https://doi.org/10.1182/blood-2016-11-749978

Published: 2017

Includes: Supplemental data

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis

Lenka Hovorkova, Marketa Zaliova, Nicola C Venn, Walter Muskovic, Jodie E Giles, Jana Linhartova, Katerina Machova Polakova, Peter J Shaw, Rosemary Sutton, Jan Stary, Jan Trka, Jan Zuna

Blood (2015) 126 (23): 3727.

https://doi.org/10.1182/blood.V126.23.3727.3727

Published: 2015

Journal Articles

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Blood (2015) 126 (23): 346.

https://doi.org/10.1182/blood.V126.23.346.346

Published: 2015

Journal Articles

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Klara Srutova, Nikola Curik, Koblihova Jitka, Filipp Savvulidi, Hana Klamova, Danilo Perrotti, Tomas Stopka, Katerina Machova Polakova

Blood (2015) 126 (23): 1243.

https://doi.org/10.1182/blood.V126.23.1243.1243

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)

BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months

Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions

Allele-dependent activity of promoters of genes SLC22A4 and SLC22A5 encoding imatinib transporters in chronic myeloid leukemia

DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from the clinical trial

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only